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International Union Against Cancer Staging Manuals: The new era of
data-driven revisionsValerie W. Rusch, MD,a Thomas W. Rice, MD,b John Crowley, PhD,c Eugene H. Blackstone, MD,b,d
Ramon Rami-Porta, MD,e and Peter Goldstraw, MDfEffective January 2010, the seventh editions of the American
Joint Commission (AJCC) on Cancer and the International
Union Against Cancer (UICC) Staging Manuals were pub-
lished.1,2 These result from intensive collaboration between
the UICC and the AJCC and unprecedented efforts to
develop and analyze large international databases leading
to evidence-based revisions of the staging system. It is im-
portant for all thoracic surgeons to be aware of these revi-
sions because they directly affect our daily clinical
practice. In the previous and current issues of the Journal,
Dr Tom Rice and colleagues present ‘‘primers’’ on the
new staging systems for lung and esophageal cancer that ex-
plain in straightforward terms the revisions made for the sev-
enth edition of the staging manuals.
The previous revision of the lung cancer staging system
occurred in 1997 with the fifth edition of the staging man-
uals. It was based on analysis of a relatively small single in-
stitution (MD Anderson Cancer Center, Houston, TX)
database of 5319 cases of non–small cell lung cancers accu-
mulated since 1975. During the past 15 years, reports from
other databases increasingly challenged some of the stage
descriptors and groupings. The staging systems for small
cell lung cancer and carcinoid tumors were also not clearly
addressed in the 1997 revision. These deficiencies were
highlighted at an International Association for the Study of
Lung Cancer (IASLC) workshop held in London in 1996,3
prompting the IASLC in 1998 to establish a Lung Cancer
Staging Project and Committee, under the leadership of Pro-
fessor Peter Goldstraw of the Royal Brompton Hospital,
London, to bring together large databases available world-
wide to form recommendations for the seventh editions of
the staging manuals that would be well validated. Cancer
Research and Biostatistics (CRAB) in Seattle, Washington,
a group with extensive experience managing large clinical
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mittee, CRAB developed the data dictionary for submission
of data from institutions worldwide.4 The database included
lung tumor cases diagnosed between 1990 and 2000, a rela-
tively short interval during which staging methods have
been constant and which also allowed 5 years of follow-up
before analysis. Cases treated by all modalities of care
were included. Ultimately, a total of 81,015 analyzable cases
from 46 sources in 19 countries were entered into the IASLC
database, including 67,725 non–small cell lung cancers,
13,290 small cell lung cancers, and 513 carcinoid tumors.5
Analyses led to changes in the T and M descriptors. Briefly,
T1 and T2 were divided into ‘‘a’’ and ‘‘b’’ subcategories to
reflect the prognostic impact of tumor size. T2 tumors larger
than 7 cm were reclassified as T3. Separate tumor nodules in
the same lobe were reclassified from T4 to T3, and those in
a separate but ipsilateral lobe from M1 to T4.5,6 The M1
category was subdivided into ‘‘a’’ and ‘‘b,’’ with M1a
including contralateral lung nodules and malignant pleural
and pericardial effusions and M1b designating distant
metastases.7 The N descriptors remained unchanged, but ex-
ploratory analyses suggested that it might be appropriate in
future revisions to subdivide the N1 and N2 categories into
1a, 1b and 2a, 2b on the basis of the number of involved
lymph node stations.8 Stage groupings also changed to re-
flect the relationship between the new T and M descriptors
and overall survival. Subsequent analyses provided external
validation of the proposed changes in the staging system
through its application to the Surveillance, Epidemiology,
and End Results Program database,9 defined important prog-
nostic factors,10 and showed that the new staging system was
also applicable to small cell lung cancer11 and carcinoid tu-
mors.12 The IASLC recommendations were accepted in full
by the UICC and AJCC, and were published in the first
organ-specific guidance to the TNM classification in Lung
Cancer last year.13,14
The esophageal cancer staging system was also revised
through an analogous effort, in this case initiated by the
AJCC. As for lung cancer, there had been no revisions in
the esophageal cancer staging system for the 2 previous edi-
tions of the staging manual. A growing body of literature
concerning factors associated with survival, including both
anatomic and nonanatomic cancer characteristics, suggested
that the staging system in the sixth edition of the staging
manual no longer accurately categorized tumors. In addition,
there was discordance between the esophageal and therdiovascular Surgery c Volume 139, Number 4 819
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which was based on lymph node anatomic location for
esophageal tumors and the number of involved lymph nodes
for gastric tumors. These differences made it difficult to
stage the increasingly common adenocarcinomas of the gas-
troesophageal junction that theoretically could be classified
according to either staging system. Therefore, the AJCC
Lung and Esophagus Taskforce spearheaded an initiative
to develop a data-driven staging system by forming the
Worldwide Esophageal Cancer Collaboration (WECC) un-
der the leadership of Drs Tom Rice and Eugene Blackstone
at the Cleveland Clinic. Through the WECC, data were as-
sembled on more than 7000 patients in 13 institutions on 3
continents, 4627 of whom underwent surgery alone for can-
cers of the esophagus and gastroesophageal junction. In sev-
eral consensus meetings, analyses of the WECC data were
discussed with the AJCC Digestive Cancer Task Force and
the UICC to harmonize the esophageal and gastric staging
systems and to arrive at final recommendations for revision
of the esophageal cancer staging system. Use of a novel sta-
tistical methodology, Random Forests, allowed self-
validation of the analyses.15
Key changes in the esophageal cancer staging system in-
clude (1) specific definitions of the anatomic boundaries of
the cervical, upper, middle, and lower thoracic esophagus
and the gastroesophageal junction; (2) recognition of the in-
fluence of tumor histology and grade on outcome, especially
in early-stage tumors through separate classifications for
squamous cell carcinomas and adenocarcinomas; (3) inclu-
sion of gastroesophageal junction tumors into the esopha-
geal staging system, because the survival of these tumors
after resection differs from that of more distal gastric can-
cers; (4) classification of high-grade dysplasia as Tis (in
situ carcinoma); (5) subclassification of T4 into ‘‘a’’ and
‘‘b’’; (6) redefinition of regional nodes as all periesophageal
lymph nodes extending from the cervical to the celiac
regions; (7) revision of the basis of N staging from anatomic
location to the number of involved lymph nodes (N0 ¼ 0,
N1¼ 1–2, N2¼ 3–6, and N3¼ 7 lymph nodes involved);
(8) elimination of subclassification of M; and (9) extensive
revision of the stage groupings.
The pivotal aspect of both of these landmarks efforts is the
development of large international databases to allow
evidence-based revisions of staging systems with data man-
agement and analyses performed by statistical centers expe-
rienced in handling large datasets. In addition, although
collaboration between the AJCC and the UICC has formally
existed since the 1980s, it was more coordinated for the sev-
enth edition of the staging manuals than in the past, thereby
eliminating previous discrepancies between the 2 manuals.
A similar effort is now under way in malignant pleural me-
sothelioma under the aegis of the IASLC, CRAB, and the In-
ternational Mesothelioma Interest Group, and another one
may be possible in the future for thymic malignancies. How-820 The Journal of Thoracic and Cardiovascular Surgever, the databases for lung and esophageal cancers, al-
though impressive, are imperfect. Both were collected
retrospectively and therefore neither totally accurate nor suf-
ficiently granular. The esophageal database was completely
based on pathologic staging from patients treated surgically
because information on patients treated nonsurgically was
not easily accessible and, given the lack of staging examina-
tions required in past trials of chemotherapy and radiation,
would not have provided the degree of precision needed
for the planned analyses. The data for patients with lung can-
cer managed surgically were heavily dependent on Japanese
sources. Participation by North American surgeons was dis-
appointingly low. To address these issues, data collection,
primarily under the direction of the IASLC Staging Commit-
tee, is now being undertaken prospectively.16 Concerted at-
tempts are being made to obtain both clinical and pathologic
staging with truly worldwide representation from patients
with both early- and advanced-stage disease. Current staging
is still primarily dependent on TNM information. However,
especially in lung cancer, rapid advances in molecular med-
icine during the past 6 years have shown the importance of
also classifying tumors on the basis of molecular features.
In addition, a recently completed multidisciplinary revision
of the histologic classification of lung adenocarcinoma may
influence future revisions of the staging system.17 Thus, it
will be important to consider tumor histologic subtype and
molecular data in the analyses of prospectively collected da-
tasets. Broad participation by the international thoracic sur-
gical community is key to the success of these efforts.
Groups interested in submitting data on patients with lung
cancer or malignant mesothelioma should contact
information@crab.org with ‘‘IASLC Staging Project’’ in
the subject line. Groups interested in submitting data on
patients with esophageal cancer should contact Drs Tom
Rice or Gene Blackstone at WECC.References
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